Bristol-Myers Squibb Expects Solid Q2 Ahead of Bigger H2, RBC Says
() -- Bristol-Myers Squibb (BMY) is expected to boast a "solid" Q2 in line with expectations on revenue and earnings ahead of what is expected to be a "pivotal" H2, RBC Capital Markets said in note Friday. RBC noted a lack of "idiosyncrasies" in the company's Q2. "It's encouraging to see Bristol-Myers Squibb continue t